The results from all of these studies supported the tumor suppressor properties of IL-24 and resulted in the testing of adenovirus-mda-7 (INGN-241)-based cancer gene therapy in a phase I clinical trial for solid tumors [36]. The gene discussed is IL24; the disease is neoplasm.